TScan Approves Retention Bonuses and RSUs for CEO and CLO Amid Restructuring
TCRX is trading near its 52-week low of $0.31 (4.5% above the low).
Summary
TScan Therapeutics granted retention awards to its CEO and CLO — $1.24 million in cash plus 3.45 million RSUs — as the company restructures and seeks capital.
Key Events · Executive and Board Changes · TCRX
-
Retention Program Approved
Compensation Committee approved cash and equity retention awards for CEO Gavin MacBeath and CLO Zoran Zdraveski on September 8, 2026.
-
Cash Awards Total $1.24M
CEO MacBeath to receive $822,000 and CLO Zdraveski $416,000, with half tied to a clinical milestone for the in vivo solid tumor program.
-
3.45M RSUs Granted
CEO to receive 2,400,000 RSUs and CLO 1,050,000 RSUs under the 2021 Equity Incentive Plan, with one-third vesting upon a financing milestone and the remainder over two years.
-
Context: Restructuring and Going Concern
Follows a 75% workforce reduction and Phase 3 trial pause announced September 2, 2026, and a going-concern warning from the August 12, 2026 10-Q.
Analysis · TCRX · Life Sciences
TScan Therapeutics approved a retention program for CEO Gavin MacBeath and CLO Zoran Zdraveski, including cash awards of $822,000 and $416,000 respectively, plus 2,400,000 and 1,050,000 restricted stock units. The awards vest in part upon a financing milestone and a clinical milestone for the in vivo solid tumor program. This comes just nine days after the company announced a 75% workforce reduction and paused its Phase 3 ALLOHA-2 trial due to capital constraints, and three weeks after Amgen terminated a collaboration worth over $500 million in potential milestones. The retention program signals the board is trying to keep critical leadership in place while the company navigates a going-concern warning and seeks new financing.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRX was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5M. The 52-week trading range was $0.31 to $2.57. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.